Nusinersen - Biogen/Ionis Pharmaceuticals
Alternative Names: BIIB-058; IONIS-SMNRx; ISIS-396443; ISIS-SMNRx; SpinrazaLatest Information Update: 03 Jul 2025
At a glance
- Originator Cold Spring Harbor Laboratory; Isis Pharmaceuticals
- Developer Biogen; Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference; Survival of motor neuron 2 protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Spinal muscular atrophy
Most Recent Events
- 27 Jun 2025 Efficacy and adverse events data from a phase II/III DEVOTE trial in Spinal muscular atrophy released by Biogen
- 27 Jun 2025 Efficacy and safety data from a phase II NURTURE trial in Spinal muscular atrophy released by Biogen
- 12 Feb 2025 FDA assigns PDUFA action date of 22/09/2025 for Nusinersen for Spinal muscular atrophy